Vertex to seek approval of IgAN drug after Phase III success [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Vertex Pharmaceuticals will head to US regulators after its immunoglobulin A nephropathy (IgAN) drug povetacicept was successful in a Phase III trial. The ongoing Phase III RAINER trial (NCT06564142) met its primary endpoint, with patients treated with 80mg povetacicept once every four weeks achieving a 52% reduction in urine protein to creatinine ratio (UPCR) after 36 weeks. The placebo-adjusted UPCR reduction of 49.8% was clinically and statistically meaningful at the same timepoint. The reduction in proteinuria was consistent across all pre-specified subgroups. One of the trial's secondary endpoints of serum galactose-deficient IgA1 reduction was also met, with povetacicept-treated patients achieving a 77.4% reduction compared to a 9.1% increase in the placebo group, yielding a reduction of 79.3% compared to placebo. The other secondary endpoint of haematuria resolution was achieved in 85.1% of patients who received the study drug compared with 23.4% in the placebo cohort.
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- My Top 3 Drug Stocks for March 2026 [Yahoo! Finance]Yahoo! Finance
- Assessing Vertex Pharmaceuticals (VRTX) Valuation After Positive RAINIER Trial Update And Accelerated IgAN Filing [Yahoo! Finance]Yahoo! Finance
- Block upgraded, Starbucks downgraded: Wall Street's top analyst calls [Yahoo! Finance]Yahoo! Finance
- Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals (VRTX) was upgraded by Maxim Group from "hold" to "buy". They now have a $575.00 price target on the stock.MarketBeat
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 3/17/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 144
- VRTX's page on the SEC website